<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548689</url>
  </required_header>
  <id_info>
    <org_study_id>STU00103009</org_study_id>
    <nct_id>NCT02548689</nct_id>
  </id_info>
  <brief_title>PAI-1 Expression in Non-scarring Hair Loss</brief_title>
  <official_title>Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether subjects who suffer from hair loss have increased levels
      of PAI-1 compared to age-matched control subjects. The level of PAI-1 expression will be
      determined in subjects without hair loss and in subjects with non-scarring hair loss,
      including androgenetic alopecia, telogen effluvium and alopecia areata.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the levels of PAI-1 expression in subjects with different forms of
      non-scarring hair loss and in these subjects vs normal age-matched controls. Hair loss
      subjects will have their Northwestern Memorial Hospital and Northwestern Medical Faculty
      Foundation medical records reviewed to ensure they meet inclusion and exclusion criteria. All
      subjects will have a 4 mm punch biopsy on the scalp. Tissue PAI-1 levels from scalp skin
      biopsies will be determined by immunohistochemical staining. Samples will be kept for
      approximately 15 years, after which time unused samples will be destroyed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PAI-1 expression level in scalp skin biopsy samples</measure>
    <time_frame>Baseline</time_frame>
    <description>Tissue PAI-1 expression levels will be determined by immunohistochemistry, a three-layer biotin-strepavidin system. Positive PAI-1 expression per total tissue area will be quantified using the color-picker function in imaging software.The PAI-1 expression found in normal scalps will be compared to those found in scalps with hair loss.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <condition>Telogen Effluvium</condition>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Non-scarring hair loss</arm_group_label>
    <description>Patients seen at Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician offices that have undergone evaluation for hair loss and have a diagnosis of androgenetic alopecia, telogen effluvium or alopecia areata.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Age-matched controls who do not have a history of hair loss and have normal scalp skin without evidence of hair loss.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin tissue will be formalin-fixed overnight at room temperature, processed and paraffin
      embedded. Six micron thick sections will be prepared. Tissue blocks and slides will be stored
      at room temperature. All samples will be de-identified.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All hair loss subjects will be recruited from patients seen at Northwestern Memorial
        Hospital or Northwestern Medical Faculty Foundation physicians offices. Age-matched control
        subjects will be recruited by either 1) the use of flyers displayed in the hospital and
        surrounding community, or 2) will be identified during a clinic visit at Northwestern
        Memorial Hospital or Northwestern Medical Faculty Foundation physician offices.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age-matched control subjects who do not have a history of hair loss

          -  A clinical and pathologic diagnosis of androgenetic alopecia, telogen effluvium,
             alopecia areata or normal scalp skin

          -  All subjects must have given signed, informed consent prior to registration in study

        Exclusion Criteria:

          -  History of previous hair transplantation

          -  Current and past use of medications topically on the scalp

          -  Clinical or pathologic diagnosis of a scarring alopecia

          -  History of inflammatory conditions of the scalp such as psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Colavincenzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasmeen Ali</last_name>
    <phone>312-503-5906</phone>
    <email>yasmeen.ali@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmeen Ali</last_name>
      <phone>312-503-5906</phone>
      <email>yasmeen.ali@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Maria Colavincenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Vaughan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekaterina Klyachko, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheila Murphy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. 2001 Jan;27(1):53-4.</citation>
    <PMID>11231244</PMID>
  </reference>
  <reference>
    <citation>Scheinfeld N. A review of hormonal therapy for female pattern (androgenic) alopecia. Dermatol Online J. 2008 Mar 15;14(3):1. Review.</citation>
    <PMID>18627703</PMID>
  </reference>
  <reference>
    <citation>Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992 Jun;26(6):926-31.</citation>
    <PMID>1607410</PMID>
  </reference>
  <reference>
    <citation>Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993 Oct;29(4):568-75.</citation>
    <PMID>8408792</PMID>
  </reference>
  <reference>
    <citation>Ogunmakin KO, Rashid RM. Alopecia: the case for medical necessity. Skinmed. 2011 Mar-Apr;9(2):79-84. Review.</citation>
    <PMID>21548511</PMID>
  </reference>
  <reference>
    <citation>Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008 Oct;59(4):547-66; quiz 567-8. doi: 10.1016/j.jaad.2008.07.001. Review.</citation>
    <PMID>18793935</PMID>
  </reference>
  <reference>
    <citation>Mounsey AL, Reed SW. Diagnosing and treating hair loss. Am Fam Physician. 2009 Aug 15;80(4):356-62. Review.</citation>
    <PMID>19678603</PMID>
  </reference>
  <reference>
    <citation>Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010 Jun;11(8):1295-304. doi: 10.1517/14656561003752730. Review.</citation>
    <PMID>20426708</PMID>
  </reference>
  <reference>
    <citation>Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):130-6. Review.</citation>
    <PMID>22409453</PMID>
  </reference>
  <reference>
    <citation>Schweiger ES, Boychenko O, Bernstein RM. Update on the pathogenesis, genetics and medical treatment of patterned hair loss. J Drugs Dermatol. 2010 Nov;9(11):1412-9. Review.</citation>
    <PMID>21061765</PMID>
  </reference>
  <reference>
    <citation>Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010 Oct;146(10):1141-50. doi: 10.1001/archdermatol.2010.256. Review.</citation>
    <PMID>20956649</PMID>
  </reference>
  <reference>
    <citation>Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 1995 Jul 3;14(13):2969-77.</citation>
    <PMID>7621813</PMID>
  </reference>
  <reference>
    <citation>Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, Vaughan DE. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost. 2007 Jul;5(7):1500-8. Epub 2007 Apr 16.</citation>
    <PMID>17439629</PMID>
  </reference>
  <reference>
    <citation>Bahta AW, Farjo N, Farjo B, Philpott MP. Premature senescence of balding dermal papilla cells in vitro is associated with p16(INK4a) expression. J Invest Dermatol. 2008 May;128(5):1088-94. Epub 2007 Nov 8.</citation>
    <PMID>17989730</PMID>
  </reference>
  <reference>
    <citation>Simonetti O, Lucarini G, Bernardini ML, Simoncini C, Biagini G, Offidani A. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. Br J Dermatol. 2004 May;150(5):940-8.</citation>
    <PMID>15149507</PMID>
  </reference>
  <reference>
    <citation>Tr√ºeb RM. Oxidative stress in ageing of hair. Int J Trichology. 2009 Jan;1(1):6-14. doi: 10.4103/0974-7753.51923.</citation>
    <PMID>20805969</PMID>
  </reference>
  <reference>
    <citation>Balsara RD, Castellino FJ, Ploplis VA. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem. 2006 Aug 11;281(32):22527-36. Epub 2006 Jun 19.</citation>
    <PMID>16785241</PMID>
  </reference>
  <reference>
    <citation>Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 2006 Aug;8(8):877-84. Epub 2006 Jul 23.</citation>
    <PMID>16862142</PMID>
  </reference>
  <reference>
    <citation>Ploplis VA, Balsara R, Sandoval-Cooper MJ, Yin ZJ, Batten J, Modi N, Gadoua D, Donahue D, Martin JA, Castellino FJ. Enhanced in vitro proliferation of aortic endothelial cells from plasminogen activator inhibitor-1-deficient mice. J Biol Chem. 2004 Feb 13;279(7):6143-51. Epub 2003 Nov 18.</citation>
    <PMID>14625301</PMID>
  </reference>
  <reference>
    <citation>Takeshita K, Yamamoto K, Ito M, Kondo T, Matsushita T, Hirai M, Kojima T, Nishimura M, Nabeshima Y, Loskutoff DJ, Saito H, Murohara T. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, &quot;Klotho&quot; mouse. Semin Thromb Hemost. 2002 Dec;28(6):545-54.</citation>
    <PMID>12536348</PMID>
  </reference>
  <reference>
    <citation>Vaughan DE. PAI-1 antagonists: the promise and the peril. Trans Am Clin Climatol Assoc. 2011;122:312-25.</citation>
    <PMID>21686234</PMID>
  </reference>
  <reference>
    <citation>Vaughan DE, De Taeye BM, Eren M. PAI-1 antagonists: predictable indications and unconventional applications. Curr Drug Targets. 2007 Sep;8(9):962-70. Review.</citation>
    <PMID>17896947</PMID>
  </reference>
  <reference>
    <citation>Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989 Jan;79(1):101-6.</citation>
    <PMID>2491971</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Maria Colavincenzo</investigator_full_name>
    <investigator_title>Assistant Professor in Dermatology</investigator_title>
  </responsible_party>
  <keyword>alopecia</keyword>
  <keyword>hair loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

